Equities By Region UK Pharmaceuticals & Health

AstraZeneca share price: Group wraps up deal for European rights to heart drug

Share this article!

AstraZeneca (LON:AZN) has wrapped up a deal to divest the European rights to its heart drug Atacand, the blue-chip company has said. The sale, first announced in July, comes as the group looks to offload non-core assets and reinvest in its main therapy areas.

AstraZeneca’s share price has slipped into the red in today’s session, having given up 0.34 percent to 5,943.00p as of 10:32 BST. The stock is underperforming the broader UK market, with the benchmark FTSE 100 index having started the new month on the front foot and currently standing 0.07 percent higher at 7,515.70 points. The group’s shares have added just over a fifth to their value over the past year, as compared with about a near two-percent gain in the Footsie.

AstraZeneca wraps up Atacand deal

AstraZeneca announced in a statement today that it had  completed an agreement with Cheplapharm Arzneimittel for the commercial rights to Atacand and Atacand Plus in Europe. Under the terms of the deal, the FTSE 100 group received a payment of $200 million, while a time-bound payment of $10 million as well as sales-contingent milestones will also be payable.

The Anglo-Swedish group will continue to manufacture and supply the treatments under a supply agreement and will continue to commercialise the medicines in all markets where it still holds the rights.

Analysts on Anglo-Swedish drugmaker

Goldman Sachs, which sees AstraZeneca as a ‘sell,’ set a price target of 4,080p on the shares last week, while JPMorgan Chase & Co, which rates the company as a ‘buy,’ set a valuation on the shares of 6,500p. According to MarketBeat, the blue-chip group currently has a consensus ‘buy’ rating and an average price target of 5,760.47p.

As of 10:44 BST, Monday, 01 October, AstraZeneca plc share price is 5,941.00p.

Add Comment

Investing is speculative. When investing your capital is at risk. This site is not intended for use in jurisdictions in which the trading or investments described are prohibited and should only be used by such persons and in such ways as are legally permitted. Your investment may not qualify for investor protection in your country or state of residence, so please conduct your own due diligence. This website is free for you to use but we may receive commission from the companies we feature on this site. Click here for more information.